Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug entities : Ionis pharmaceuticals, inc. save search
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS
Published: 2024-03-19 (Crawled : 12:30) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.33%
H: 1.89%
C: 0.64%
drug health genetic als review treatment canada submission
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Published: 2024-02-15 (Crawled : 13:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -1.53%
H: 3.16%
C: -6.29%
fda drug designation
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Published: 2023-03-07 (Crawled : 12:20) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: -2.27%
treatment fda drug application eplontersen
Akeso's Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China Akeso, Biopharma announced that the Center for Drug Evalua...
Published: 2022-11-14 (Crawled : 06:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.35%
H: 4.08%
C: 1.47%
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: -13.42%
H: 4.11%
C: -3.5%
ak112 biopharma designation drug granted china therapy
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen
Published: 2022-10-17 (Crawled : 12:00) - globenewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.97%
H: 1.62%
C: -0.62%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.54%
H: 2.99%
C: 1.32%
drug extension application review
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
Published: 2022-07-26 (Crawled : 12:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 1.96%
H: 0.2%
C: -2.61%
fda drug genetic als application grants review
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
Published: 2022-07-26 (Crawled : 12:00) - globenewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 1.96%
H: 0.2%
C: -2.61%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.42%
H: 3.54%
C: 2.01%
fda drug genetic als application grants review
Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
Published: 2022-06-13 (Crawled : 12:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.29%
H: 0.13%
C: -1.7%
treatment fda rare drug disease designation
Global Genitourinary Drugs Market Research Report to 2027 - Increasing Prevalence of Genitourinary Disorders is Driving Growth
Published: 2022-04-26 (Crawled : 14:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 2.56%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.13%
H: 0.06%
C: -0.69%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 3.08%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.47%
H: 0.83%
C: -1.44%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 2.0%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.34%
H: 1.41%
C: -1.17%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.12%
H: 0.07%
C: -5.13%
research report growth market drug
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Published: 2022-03-28 (Crawled : 12:20) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -1.12%
H: 1.96%
C: -1.05%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.42%
H: 1.04%
C: 0.76%
drug results topline sclerosis phase 1
Ionis announces eplontersen receives orphan drug designation from U.S. FDA
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -1.45%
H: 7.89%
C: 7.31%
fda drug orphan drug designation eplontersen
Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -1.45%
H: 7.89%
C: 7.31%
drug granted orphan drug grant designation eplontersen
Drug Trial Snapshot: TEGSEDI
Published: 2021-05-20 (Crawled : 16:03) - fda.gov
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.14%
H: 5.31%
C: 3.25%
trial drug
Drug Trial Snapshot: TEGSEDI
Published: 2021-03-18 (Crawled : 16:03) - fda.gov
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.66%
H: 2.34%
C: -0.38%
drug trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.